Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03619551 · ClinicalTrials.gov registry record · Phase 2
Conditioning SCID Infants Diagnosed Early
A Phase 2 study of SCI/D, sponsored by Center for International Blood and Marrow Transplant Research.
- Active
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT03619551 is a Phase 2 study of SCI/D that is active but no longer recruiting, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 56 participants, above the 39-participant average among 3 other SCI/D trials with a reported enrollment target (44% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT03619551, a Phase 2 study of SCI/D, is active but no longer recruiting, sponsored by Center for International Blood and Marrow Transplant Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
Conditions Studied
Interventions
- DRUG Busulfan
- DEVICE Cell processing for TCRαβ+/CD19+ depletion
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- UCLA Center for Health Sciences - Los Angeles
- Rady Children's Hospital, San Diego - San Diego
- University of California San Francisco Medical Center - Peds - San Francisco
Florida
- Shands HealthCare & University of Florida - Gainesville
- University of Miami/Jackson Memorial Hospital - Miami
- All Children's Hospital - St. Petersburg
Michigan
- The University of Michigan - Ann Arbor
- Helen DeVos Children's - Grand Rapids
Alabama
- Univeristy of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona and Phoenix Children's Hospital - Phoenix
Colorado
- University of Colorado - Children's Hospital - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta at Egleston - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03619551
The ClinicalTrials.gov registry entry for NCT03619551 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 39-participant average among 3 other SCI/D trials with a reported enrollment target (44% higher). The listed sponsor is Center for International Blood and Marrow Transplant Research, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SCI/D appearing as the primary indexed condition, and to 2 interventions - of which Busulfan is the first listed.
NCT03619551 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT03619551 about?
NCT03619551 is a clinical study titled "Conditioning SCID Infants Diagnosed Early". The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this appr...
What is the current status of trial NCT03619551?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2018-10-22. Estimated completion is 2028-12-01.
What conditions does trial NCT03619551 study?
This clinical trial studies the following conditions: SCI/D.
What interventions are being tested in trial NCT03619551?
The interventions under investigation include: Busulfan (DRUG), Cell processing for TCRαβ+/CD19+ depletion (DEVICE).
Who is sponsoring clinical trial NCT03619551?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03619551 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SCI/D
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Hypercapnia Treatment on Respiratory Recovery After Spinal Cord Injury
RECRUITING · NA
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
ACTIVE NOT RECRUITING · NA
-
Novel by Upper Airway Respiratory Muscle Training to Treat OSA in Chronic SCI
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.